FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056549675> ?p ?o ?g. }

• W2056549675 endingPage "852" @default.
• W2056549675 startingPage "848" @default.
• W2056549675 abstract "Posttransplant lymphoproliferative disorder (PTLD) has been observed with increasing frequency consequent to the availability of more effective and potent immunosuppression. Prior work suggested that a peripheral blood monitoring strategy detecting peripheral B lymphoproliferation was effective in the early diagnosis of PTLD among 7 of 179 (3.9%) consecutive transplant recipients. Each of those seven patients received at least one course of antithymocyte globulin, Minnesota antilymphocyte globulin, or OKT3 before developing PTLD.To determine whether antiviral prophylaxis might reduce the incidence of PTLD, a subsequent group of 198 consecutive recipients received either ganciclovir or acyclovir during antilymphocyte antibody administration. When the donor or recipient were cytomegalovirus-seropositive, ganciclovir was given; acyclovir was used when both were cytomegalovirus-seronegative. Baseline and protocol posttransplant cell surface profiles were obtained using immunofluorescence and flow cytometry to detect T cells, lymphocyte activation markers, and the CD19 B cell antigen.Demographic factors, including the incidence of recipients more than 50 years of age, non-Caucasians, previous transplantation, and diabetes mellitus, were similar in both groups. Additionally, the number of patients receiving antilymphocyte preparations was similar. However, only one patient (0.5%) from the latter group who received preemptive antiviral therapy developed PTLD. Although elevations in CD19+ B cells preceded clinical PTLD among each of the seven earlier patients, evidence of peripheral B cell proliferation was not demonstrated for the sole patient from the latter group, which suggests a possible effect of antiviral therapy.Prophylactic antiviral therapy may reduce the sensitivity of peripheral monitoring for B lymphoproliferation, but the dramatic reduction in PTLD incidence strongly supports its use among transplant recipients at risk." @default.
• W2056549675 created "2016-06-24" @default.
• W2056549675 creator A5002363138 @default.
• W2056549675 creator A5023473082 @default.
• W2056549675 creator A5038392036 @default.
• W2056549675 creator A5053454973 @default.
• W2056549675 creator A5055641686 @default.
• W2056549675 creator A5058155341 @default.
• W2056549675 creator A5062372956 @default.
• W2056549675 creator A5064351594 @default.
• W2056549675 creator A5084850960 @default.
• W2056549675 creator A5085820214 @default.
• W2056549675 date "1997-09-01" @default.
• W2056549675 modified "2023-09-25" @default.
• W2056549675 title "REDUCED INCIDENCE OF EPSTEIN-BARR VIRUS-ASSOCIATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER USING PREEMPTIVE ANTIVIRAL THERAPY1" @default.
• W2056549675 cites W1977930329 @default.
• W2056549675 cites W1984344279 @default.
• W2056549675 cites W1987211357 @default.
• W2056549675 cites W2004966846 @default.
• W2056549675 cites W2010488262 @default.
• W2056549675 cites W2030352916 @default.
• W2056549675 cites W2033032321 @default.
• W2056549675 cites W2036402660 @default.
• W2056549675 cites W2042670391 @default.
• W2056549675 cites W2042849224 @default.
• W2056549675 cites W2050306266 @default.
• W2056549675 cites W2051159620 @default.
• W2056549675 cites W2080062050 @default.
• W2056549675 cites W2113209260 @default.
• W2056549675 cites W2137858837 @default.
• W2056549675 cites W2148185719 @default.
• W2056549675 cites W2157575408 @default.
• W2056549675 cites W2338358489 @default.
• W2056549675 cites W2341259055 @default.
• W2056549675 cites W4243566326 @default.
• W2056549675 cites W4249599642 @default.
• W2056549675 cites W51893192 @default.
• W2056549675 doi "https://doi.org/10.1097/00007890-199709270-00010" @default.
• W2056549675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9326409" @default.
• W2056549675 hasPublicationYear "1997" @default.
• W2056549675 type Work @default.
• W2056549675 sameAs 2056549675 @default.
• W2056549675 citedByCount "171" @default.
• W2056549675 countsByYear W20565496752012 @default.
• W2056549675 countsByYear W20565496752013 @default.
• W2056549675 countsByYear W20565496752014 @default.
• W2056549675 countsByYear W20565496752015 @default.
• W2056549675 countsByYear W20565496752016 @default.
• W2056549675 countsByYear W20565496752017 @default.
• W2056549675 countsByYear W20565496752018 @default.
• W2056549675 countsByYear W20565496752019 @default.
• W2056549675 countsByYear W20565496752020 @default.
• W2056549675 countsByYear W20565496752021 @default.
• W2056549675 countsByYear W20565496752022 @default.
• W2056549675 countsByYear W20565496752023 @default.
• W2056549675 crossrefType "journal-article" @default.
• W2056549675 hasAuthorship W2056549675A5002363138 @default.
• W2056549675 hasAuthorship W2056549675A5023473082 @default.
• W2056549675 hasAuthorship W2056549675A5038392036 @default.
• W2056549675 hasAuthorship W2056549675A5053454973 @default.
• W2056549675 hasAuthorship W2056549675A5055641686 @default.
• W2056549675 hasAuthorship W2056549675A5058155341 @default.
• W2056549675 hasAuthorship W2056549675A5062372956 @default.
• W2056549675 hasAuthorship W2056549675A5064351594 @default.
• W2056549675 hasAuthorship W2056549675A5084850960 @default.
• W2056549675 hasAuthorship W2056549675A5085820214 @default.
• W2056549675 hasBestOaLocation W20565496751 @default.
• W2056549675 hasConcept C120665830 @default.
• W2056549675 hasConcept C121332964 @default.
• W2056549675 hasConcept C126322002 @default.
• W2056549675 hasConcept C159654299 @default.
• W2056549675 hasConcept C203014093 @default.
• W2056549675 hasConcept C2522874641 @default.
• W2056549675 hasConcept C2776409557 @default.
• W2056549675 hasConcept C2776995267 @default.
• W2056549675 hasConcept C2777732132 @default.
• W2056549675 hasConcept C2777965375 @default.
• W2056549675 hasConcept C2778957590 @default.
• W2056549675 hasConcept C2779338263 @default.
• W2056549675 hasConcept C2779820661 @default.
• W2056549675 hasConcept C2780252810 @default.
• W2056549675 hasConcept C2780727368 @default.
• W2056549675 hasConcept C2911091166 @default.
• W2056549675 hasConcept C61511704 @default.
• W2056549675 hasConcept C71924100 @default.
• W2056549675 hasConcept C90924648 @default.
• W2056549675 hasConceptScore W2056549675C120665830 @default.
• W2056549675 hasConceptScore W2056549675C121332964 @default.
• W2056549675 hasConceptScore W2056549675C126322002 @default.
• W2056549675 hasConceptScore W2056549675C159654299 @default.
• W2056549675 hasConceptScore W2056549675C203014093 @default.
• W2056549675 hasConceptScore W2056549675C2522874641 @default.
• W2056549675 hasConceptScore W2056549675C2776409557 @default.
• W2056549675 hasConceptScore W2056549675C2776995267 @default.
• W2056549675 hasConceptScore W2056549675C2777732132 @default.
• W2056549675 hasConceptScore W2056549675C2777965375 @default.
• W2056549675 hasConceptScore W2056549675C2778957590 @default.
• W2056549675 hasConceptScore W2056549675C2779338263 @default.

• next